In the original version of this article, the second figure contained an error. The image has been updated. It’s important for engineers to have a good, working ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback